Cytosorbents (CTSO) to Release Earnings on Monday

Cytosorbents (NASDAQ:CTSO) is projected to post its quarterly earnings results after the market closes on Monday, March 31st. Analysts expect Cytosorbents to post earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Cytosorbents Price Performance

Cytosorbents stock opened at $1.00 on Friday. The firm has a market capitalization of $54.68 million, a PE ratio of -2.78 and a beta of 0.78. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The firm’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $1.05. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Wall Street Analyst Weigh In

Several analysts have recently commented on CTSO shares. StockNews.com started coverage on shares of Cytosorbents in a research report on Wednesday. They issued a “hold” rating on the stock. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $4.67.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.